← United States · Coverage record
US · SEC FORM 4
IN8BIO, INC.
INAB · Nasdaq · CIK 0001740279 · Healthcare · Biotechnology
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
1 Form 4 transaction lines observed in the same window
0 sales · 1 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
—
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2023-09-13 · Graff Jeremy R..
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 46,440
- Previous report
- 63,110
- Avg daily volume
- 53,488
- Days to cover
- ≤ 1.0
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2023-09-13 | Graff Jeremy R. | Purchase (P) | Common Stock | 2,500 | USD 0.95 | USD 2,375 | SEC filing ↗ |
| 2023-08-25 | McCall Patrick | Purchase (P) | Common Stock | 1,000 | USD 1.03 | USD 1,030 | SEC filing ↗ |
| 2023-08-24 | Ho William Tai-Wei | Purchase (P) | Common Stock | 23,800 | USD 1.05 | USD 24,990 | SEC filing ↗ |
| 2022-12-12 | BIOS Equity Partners III, LP; Bios Equity Partners II, LP; Cavu Advisors, LLC; Cavu Management, LP; Kreis Leslie W. | Purchase (P) | Common Stock | 75,001 | USD 2.48 | USD 186,002 | SEC filing ↗ |
| 2022-12-12 | BIOS Advisors GP, LLC; BIOS Capital Management, LP; BIOS Fund II NT, LP; BIOS Fund II QP, LP; BIOS Fund II, LP; BIOS Fund III NT, LP; BIOS Fund III QP, LP; BIOS Fund III, LP; BIOS Incysus Co-Invest I, LP; Fletcher Aaron G.L. | Purchase (P) | Common Stock | 75,001 | USD 2.48 | USD 186,002 | SEC filing ↗ |
| 2022-09-28 | BIOS Equity Partners III, LP; Bios Equity Partners II, LP; Cavu Advisors, LLC; Cavu Management, LP; Kreis Leslie W. | Purchase (P) | Common Stock | 25,000 | USD 2.02 | USD 50,500 | SEC filing ↗ |
| 2022-09-28 | BIOS Advisors GP, LLC; BIOS Capital Management, LP; BIOS Fund II NT, LP; BIOS Fund II QP, LP; BIOS Fund II, LP; BIOS Fund III NT, LP; BIOS Fund III QP, LP; BIOS Fund III, LP; BIOS Incysus Co-Invest I, LP; Fletcher Aaron G.L. | Purchase (P) | Common Stock | 25,000 | USD 2.02 | USD 50,500 | SEC filing ↗ |
| 2022-08-29 | BIOS Equity Partners III, LP; BIOS Fund II NT, LP; BIOS Fund II QP, LP; BIOS Fund II, LP; BIOS Incysus Co-Invest I, LP; Bios Equity Partners II, LP; Cavu Advisors, LLC; Cavu Management, LP; Kreis Leslie W. | Purchase (P) | Common Stock | 40,000 | USD 2.02 | USD 80,800 | SEC filing ↗ |
| 2022-08-29 | BIOS Equity Partners III, LP; BIOS Fund II NT, LP; BIOS Fund II QP, LP; BIOS Fund II, LP; BIOS Incysus Co-Invest I, LP; Bios Equity Partners II, LP; Cavu Advisors, LLC; Cavu Management, LP; Fletcher Aaron G.L. | Purchase (P) | Common Stock | 40,000 | USD 2.02 | USD 80,800 | SEC filing ↗ |
| 2022-08-26 | BIOS Equity Partners III, LP; BIOS Fund II NT, LP; BIOS Fund II QP, LP; BIOS Fund II, LP; BIOS Incysus Co-Invest I, LP; Bios Equity Partners II, LP; Cavu Advisors, LLC; Cavu Management, LP; Kreis Leslie W. | Purchase (P) | Common Stock | 11,214 | USD 2.01 | USD 22,540 | SEC filing ↗ |
| 2022-08-26 | BIOS Equity Partners III, LP; BIOS Fund II NT, LP; BIOS Fund II QP, LP; BIOS Fund II, LP; BIOS Incysus Co-Invest I, LP; Bios Equity Partners II, LP; Cavu Advisors, LLC; Cavu Management, LP; Fletcher Aaron G.L. | Purchase (P) | Common Stock | 11,214 | USD 2.01 | USD 22,540 | SEC filing ↗ |
| 2022-08-17 | BIOS Equity Partners III, LP; BIOS Fund II NT, LP; BIOS Fund II QP, LP; BIOS Fund II, LP; BIOS Incysus Co-Invest I, LP; Bios Equity Partners II, LP; Cavu Advisors, LLC; Cavu Management, LP; Kreis Leslie W. | Purchase (P) | Common Stock | 50,000 | USD 1.93 | USD 96,500 | SEC filing ↗ |
| 2022-08-17 | BIOS Advisors GP, LLC; BIOS Capital Management, LP; BIOS Equity Partners III, LP; Cavu Management, LP; Fletcher Aaron G.L. | Purchase (P) | Common Stock | 50,000 | USD 1.93 | USD 96,500 | SEC filing ↗ |
| 2022-08-16 | Roemer Alan S. | Purchase (P) | Common Stock | 26,315 | USD 1.90 | USD 49,998 | SEC filing ↗ |
| 2022-08-16 | Rochlin Kate | Purchase (P) | Common Stock | 5,263 | USD 1.90 | USD 10,000 | SEC filing ↗ |
Form 4 evidence
7 transaction lines in the latest 365-day window; 95 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-05-27 | FAIRBAIRN EMILY | Gift (G) | Common Stock | 724,637 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-12-22 | Roemer Alan S. | Award / grant (A) | Common Stock | 36,232 | USD 1.38 | USD 50,000 | SEC filing ↗ |
| 2025-12-22 | Rochlin Kate | Award / grant (A) | Common Stock | 7,247 | USD 1.38 | USD 10,001 | SEC filing ↗ |
Show recent Form 4 evidence (7 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-05-27 | FAIRBAIRN EMILY | Gift (G) | Common Stock | 724,637 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-12-22 | Roemer Alan S. | Award / grant (A) | Common Stock | 36,232 | USD 1.38 | USD 50,000 | SEC filing ↗ |
| 2025-12-22 | Rochlin Kate | Award / grant (A) | Common Stock | 7,247 | USD 1.38 | USD 10,001 | SEC filing ↗ |
| 2025-12-22 | McCall Patrick | Award / grant (A) | Common Stock | 7,247 | USD 1.38 | USD 10,001 | SEC filing ↗ |
| 2025-12-22 | Ho William Tai-Wei | Award / grant (A) | Common Stock | 36,232 | USD 1.38 | USD 50,000 | SEC filing ↗ |
| 2025-12-22 | FAIRBAIRN EMILY | Award / grant (A) | Common Stock | 724,637 | USD 1.38 | USD 999,999 | SEC filing ↗ |
| 2025-12-22 | Brandt Peter C. | Award / grant (A) | Common Stock | 72,464 | USD 1.38 | USD 100,000 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-19 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | INAB |
| CIK | 0001740279 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 95 transaction lines from 2021-08-03 to 2026-05-27 49 P purchase lines · 0 S sale lines · 46 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.